Atrys Health Sa · BME:ATRY
Atrys Health Sa — Q1 2026 Earnings Presentation
13 slides from Atrys Health Sa's earnings presentation, May 2026
Slide 1: Financial Results Presentation 1Q 2026
Financial Results Presentation 1Q 2026
Slide 2: Highlights 1Q 26
Highlights 1Q 26 Summary Financial New organisational structure to strengthen management discipline (implemented from the second half of 2025) €37,5M + 6,3% Turnover Solid growth at the start of 2026: +6.3% in revenue and +15.4% in EBITDA compared €15,6M + 4,6% Gross Margin(MAR) with Q1 2025. € 4,1M
Slide 3: New organisational structure - 2026
New organisational structure - 2026 Previous structure New structure Corporate Corporate Oncology Diagnostics Prevention Spain Latam Portugal Spain Portugal Mexico Spain Latam Spain (Chile, Colombia, Peru, Brasil) Chile Brasil Colombia y Peru Mexico Nuclear Oncology D. imaging Laboratory Medicine Co
Slide 4: Key financials 1Q 2026
Key financials 1Q 2026 Revenues Gross Margin(MAR) EBITDA (MAR) Operating Cash Flow (MAR) +4,8% +6,3% +15,4% +55,5% 42,2% 41,6% 10,1% 10,9% 6,0% 8,8% The growth in turnover (+6.3%) compared with Q1 Increase in gross margin on turnover (+4.8%, +€0.7m), Strong EBITDA growth, driven by robust business A
Slide 5: Revenue by Geography
Revenue by Geography Revenues Portugal +9,1% 4,3M€ Mexico +128,8% 3,9M€ 11,1% 30,1% Spain Chile -0,1% (4,9%) 47,8% 20,3M€ 54,5% 6,2M€ 34,4% LatAm 11,8% Brasil +17,0% (11,5%) 12,9M€ 10,3% 1,3M€ Colombia & Peru +13,9% 1,5M€ EBITDA Portugal +1.351,7% Mexico 0,7M€ +522,9% 0,4M€ 15,9% Chile 22,7% LatAm (
Slide 6: Key financial 1Q 2026 by business segment
Key financial 1Q 2026 by business segment % SHARE OF REVENUE % OF EBITDA (MAR) BY SEGMENT BY SEGMENT Diagnostic Oncology Diagnostic Oncology ONCOLOGY DIAGNOSTICS TOTAL Revenues / EBITDA Revenues / EBITDA Revenues / EBITDA +6,3% +19,6% -6,9% 17,5% 21,1% 14,0% 10,1% 10,9% 12,2% -38,1% +15,4% +71,6% Rev
Slide 7: 1Q 26 vs 1Q 25 Consolidated
1Q 26 vs 1Q 25 Consolidated Spain: Positive performance across key business areas, with notable growth in Diagnostic Imaging (+18.7%), and Oncology Revenues (+6.8%), which offset the decline in Laboratories (-28.9%), affected by the loss of a major contract and the decline in HPV activity, which led
Slide 8: Divestment in the Prevention segment enables transformational deleveraging
Divestment in the Prevention segment enables transformational deleveraging. Net debt and interest expense are reduced Gross and net financial debt (mar) 2025 Gross and net financial debt (mar) 1Q 26 TOTAL GROSS DEBT (MAR) 190,1 NET CASH TOTAL GROSS DEBT MAR) 45,1 RECEIVED FROM ASPY SALES 143,5 BANK DE
Slide 9: Guidance 2026: We are maintaining the main figures
Guidance 2026: We are maintaining the main figures The guidance previously announced 2025 2026 at the close of the 2025 financial year remains unchanged: Revenues 141,0 156,5 +11% Reporting EBITDA 15,3 20,5 +40% CAPEX (9,3) (7,0) (24,7% Operating Cash Flow 6,0 13,5 +125% Unaudited figures in millions o
Slide 10: ANNEX I: Summary of trends in key financial indicators
ANNEX I: Summary of trends in key financial indicators Fiscal year 2023 Fiscal year 2024 Fiscal year 2025 Figures in thousands of EUR Revenues Procurements Gross Margin(MAR) % Over Revenues EBITDA(MAR) Nonrecurring expenses Adjusted EBITDA(MAR) % Over Revenues CAPEX(MAR) CAPEX Maintenance and R&D CAP
Slide 11: ANNEX II: Alternative Performance Measures Definitions (MAR)
ANNEX II: Alternative Performance Measures Definitions (MAR) Gross margin is calculated as total revenue minus cost of goods sold. The Group considers CAPEX refers to cash outflows incurred in connection with the Group’s production capacity gross margin to be a measure of its operating performance, as
Slide 12: Q&A
Q&A Marian Isach CEO Q&A Alberto Iriondo CFO
Slide 13: Find more information at atryshealth.com
Find more information at atryshealth.com